Oral therapies for diabetic retinopathy: Addressing an unmet need or a distant prospect?
Theo Empeslidis, Georgios D Panos, Konstantinos Balaskas, David RP Almeida · 2025
Read Oral therapies for diabetic retinopathy: Addressing an unmet need or a distant prospect? by Theo Empeslidis, Georgios D Panos, Konstantinos Balaskas, David RP Almeida (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12743899.txt.
Description
Theo Empeslidis and three co-authors ask whether pills taken by mouth can slow diabetes harm to the eye. Shots into the eye work, but they burden patients and clinics. Their 2025 review weighs five drug classes by how they act on the retina's shared nerve and vessel web.
One class, used for blood fats, showed steady signs of halting worsening. A second showed mixed results, with gains in some subgroups. A third showed early promise in both eyes at once. Two more classes gave patchy or flat results so far. The authors sort trial design traps, from eye-pair counts to slow-burn endpoints. They close with a research plan for proof that pills can earn a place.
Catalog record
| CREATOR | Theo Empeslidis, Georgios D Panos, Konstantinos Balaskas, David RP Almeida |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |